The invention provides a method of extracting protein from a protein source material such as egg white material. The method comprises contacting a crosslinked alginate-based carrier with the protein source material and allowing the protein to bind to the carrier, so as to form a protein-loaded carrier product. The method then comprises separating the protein-loaded carrier product from the remaining protein source material.

The invention provides a method of extracting protein from a protein source material such as egg white material. The method comprises contacting a crosslinked alginate-based carrier with the protein source material and allowing the protein to bind to the carrier, so as to form a protein-loaded carrier product. The method then comprises separating the protein-loaded carrier product from the remaining protein source material.

Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

Provided herein are compositions, proteins, polynucleotides, expression vectors, host cells, kits, and systems for producing egg white proteins, as well as methods of using the same.

Provided herein are compositions, proteins, polynucleotides, expression vectors, host cells, kits, and systems for producing egg white proteins, as well as methods of using the same.

A nanostructure for isolating or concentrating extracellular vesicles or a pathogen, includes a transferrin family protein linked on magnetic nanoparticles. The nanostructure includes a transferrin family protein, and thus has selectivity for a pathogen or extracellular vesicles capable of binding to the transferrin family protein, and the synthesized nanostructure is positively (+) charged. The nanostructure includes magnetic nanoparticles, a target material is easily and simply isolated from other materials by magnetism when a magnetic field is applied.

Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.

Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.

One aspect according to the present disclosure relates to a novel nucleic acid ligand which is a new class of nucleic acid compound, the existence of which was considered impossible in the prior art. The novel nucleic acid ligand has specific binding affinity with respect to at least two different targets having three-dimensional structures, and the binding sites for the at least two targets are formed in or from a single nucleic acid ligand. The novel nucleic acid ligand according the present disclosure can simultaneously solve several problems of existing aptamers that the prior art could not solve. One aspect according to the present disclosure relates to a novel screening method for identifying the above-mentioned novel nucleic acid ligand. The novel screening method uses a step for sequentially contacting at least two different targets having three-dimensional structures to screen a novel nucleic acid ligand that was previously thought impossible.

The present invention provides a derived peptide of a lactoferrin, a composition comprising the same and a use thereof for promoting and/or increasing lipid synthesis. The derived peptide of the lactoferrin comprises the amino acid sequence of SEQ ID NO: 01.